ERBB2

Disitamab Vedotin Plus Tislelizumab in Transurethrally Unresectable, ERBB2-Positive, Non-Muscle-Invasive Bladder Cancer: An Emerging Therapeutic Strategy

This review synthesizes evidence on disitamab vedotin combined with tislelizumab showing promising efficacy and safety in treating transurethrally unresectable ERBB2-positive very high-risk NMIBC, filling a crucial therapeutic gap for patie